The protocols of the related drugs to a total of 453 eligible patients in the study.

<p>N = number; W = week; ETW = every two weeks; EQW = every four weeks.</p

The relationship between <i>KCNH2</i> (C1956T) genetic polymorphism and the hypotensive effects of CCBs (azelnidipine & nitrendipine).

<p>Absolute changes in SBP (A), DBP (B), and MAP (C) in EH patients carrying the KCNH2 (1956,C>T) CC and CT+TT genotypes after treatment with azelnidipine or nitrendipine for 2, 4, and 6 weeks.*<i>P</i><0.05(without age, BMI, and gender adjustment), error bar indicated 95% confidence interval.</p

Stratified analyses of the difference hypotensive effects of α,β-ADR blockers between KCNH2 (1956,C>T) genotypes(CC v.s CT+TT) and age(≤55 y v.s 55 y), gender(Men v.s Women)interactions in EH patients.

*<p>P-values were with bonferroni adjust and BMI, gender ,age adjust were appropriately use in the model,ΔHR4 = heart rate change at the end of 4 weeks, ΔDBP4 = diastolic pressure change at the at the end of 4 weeks,ΔMAP4 = mean arterial pressure change at the at the end of 4 weeks, ΔPP4 = pulse pressure change at the end of 4 weeks, ΔDBP6 = diastolic pressure change at the end of 6weeks, ΔMAP6 = mean arterial pressure change at the end of 6 weeks.</p

Telmisartan PKs of 48 health males with different genotypes.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05; **<i>P</i><0.01.</p><p>PKs, pharmacokinetics; <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

The hypotensive effects of α,β-ADR blockers between KCNH2(C1966T) genotypes(CC v.s CT+TT) and age(≤55 y v.s 55 y), gender(Men v.s Women)interactions in EH patients.

*<p>P-values were with bonferroni adjust and BMI, gender ,age adjust were appropriately use in the model,ΔHR4 = heart rate change at the end of 4 weeks, ΔDBP4 = diastolic pressure change at the at the end of 4 weeks,ΔMAP4 = mean arterial pressure change at the at the end of 4 weeks,ΔDBP6 = diastolic pressure change at the end of 6weeks, ΔMAP6 = mean arterial pressure change at the end of 6 weeks.</p

The impacts of <i>ORM1</i> genotypes on the PKs and BP change(%) after 40 mg telmisartan.

<p>A, Concentration; B, AUC_(0–∞); C, SBP change(%) from the baseline; D, DBP change(%) from the baseline.</p

Summary of Genetic Variations of SNPs in this Study.

a<p>data published on hapmap; b, data calculated in this study, N = 48; N/A, no data found in hapmap.</p><p>MAF: Minor Allele frequencies; CHB: Han Chinese in Beijing, China; ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

The demographics information of the participants.

<p>BMI, body mass index.</p

The P valve of variable factors on PK and BP change parameters in the corrected models.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05;</p>**<p><i>P</i><0.01.</p><p><i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; AUC_(0–∞) the area under the plasma concentration-time curve(AUC) from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max; SBP, systolic blood pressure; DBP, diastolic blood pressure.</p

The impacts of <i>ABCC2</i> genotypes on the PKs and BP change(%) after 40 mg telmisartan.

<p>A, Concentration; B, AUC_(0–∞); C, SBP change(%) from the baseline; D, DBP change(%) from the baseline.</p